Am J Pharmacol | Volume 3, Issue 1 | Review Article | Open Access
Yao M, Tang T, Lin X and Jiang S*
Department of Respiratory Medicine, Sun Yat-sen University, China
*Correspondance to: Shanping Jiang
Fulltext PDFNowadays, novel coronavirus pneumonia, called Coronavirus Disease 2019 (COVID-19) spread rapidly to the whole world and this novel global pandemic has severely threatened the public health. To date, researchers have found that glucocorticoid may be beneficial to decrease the fatality rate in severe COVID-19 patients by a large randomized controlled trial but its specific mechanism is still in debate. This article has put forward two hypotheses about the potential mechanisms of glucocorticoid for treating COVID-19 patients. On the one hand, the progressions of COVID-19 aggravate the injury of lungs and may cause a rare histologic pattern of acute lung injury defined as Acute Fibrinous and Organizing Pneumonia (AFOP). Glucocorticoid may improve the clinical outcomes of severe COVID-19 patients by curing AFOP. On the other hand, the deterioration of COVID-19 can damage to adrenal glands and result in adrenal insufficiency. Thus, the use of glucocorticoids as replacement therapy can modulate the human metabolism and immune response and the clinical conditions of patients will improve.
Covid-19; Covid; Corona Virus; Coronavirus disease 2019;Glucocorticoid; SARS-CoV-2
Yao M, Tang T, Lin X and Jiang S. Mechanism of Glucocorticoid for Treating Severe COVID-19 Patients. Am J Pharmacol. 2020; 3(1): 1028.